6,258 Shares in Cencora, Inc. $COR Acquired by Waycross Partners LLC

Key Points

• Waycross Partners opened a new Cencora position, buying 6,258 shares worth approximately $1.88 million in the third quarter. Institutional investors collectively own 97.52% of the company’s stock.
• Cencora beat quarterly estimates, reporting EPS of $4.66 versus $4.58 expected and revenue of $88.35 billion, up 5.5% year over year.
• The company raised its quarterly dividend from $0.60 to $0.66 per share. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $368.73.

Waycross Partners LLC purchased a new position in Cencora, Inc. (NYSE:COR - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,258 shares of the company's stock, valued at approximately $1,879,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in COR. BlackRock Inc. bought a new stake in shares of Cencora during the second quarter valued at approximately $5,154,136,000. Bank of America Corp DE lifted its holdings in shares of Cencora by 6.9% in the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company's stock worth $1,300,033,000 after buying an additional 267,318 shares in the last quarter. Amundi lifted its holdings in shares of Cencora by 43.5% in the second quarter. Amundi now owns 2,229,326 shares of the company's stock worth $630,855,000 after buying an additional 676,066 shares in the last quarter. Carmignac Gestion boosted its position in shares of Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company's stock worth $494,463,000 after acquiring an additional 646,112 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Cencora during the second quarter worth $483,772,000. 97.52% of the stock is currently owned by institutional investors.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat quarterly expectations, reporting EPS of $4.66 versus estimates of $4.58 and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year. The company also issued a stronger fiscal 2027 earnings outlook, reinforcing expectations for continued growth. Cencora stock enters fiscal 2027 with stronger earnings outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 from $388 and maintained an “outperform” rating, signaling confidence in potential upside.
• Positive Sentiment: Cencora raised its dividend, adding to its appeal for income-focused investors amid market uncertainty. Stocks that hiked dividends
• Neutral Sentiment: The company is realigning its corporate structure. The available report headline does not specify the changes or their expected financial impact. Cencora realigning corporate structure
• Negative Sentiment: Despite Cencora’s earnings beat, shares came under pressure after rival Cardinal Health reported results, prompting concern about relative performance and contributing to a short-term pullback. Cencora drops while rival Cardinal Health posts a beat

Analysts Set New Price Targets

COR has been the topic of a number of research reports. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $382.00 to $390.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Wells Fargo & Company increased their price objective on shares of Cencora from $331.00 to $395.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. Argus raised their price objective on Cencora from $340.00 to $380.00 and gave the company a "buy" rating in a research report on Tuesday, October 20th. UBS Group reduced their target price on Cencora from $430.00 to $400.00 and set a "buy" rating on the stock in a report on Friday, October 16th. Finally, Morgan Stanley boosted their target price on Cencora from $346.00 to $377.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and an average target price of $368.73.

Cencora Trading Down 1.9%

COR traded down $6.30 on Friday, hitting $333.38. The company had a trading volume of 1,682,033 shares, compared to its average volume of 1,163,722. The company has a market cap of $63.62 billion, a PE ratio of 18.60, a PEG ratio of 1.73 and a beta of 0.58. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The business's fifty day simple moving average is $325.07 and its 200 day simple moving average is $317.28.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.58 by $0.08. The business had revenue of $88.35 billion for the quarter, compared to the consensus estimate of $87.95 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The company's quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.84 earnings per share. Equities research analysts expect that Cencora, Inc. will post 19.58 EPS for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be given a $0.66 dividend. This is a boost from Cencora's previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, November 13th. Cencora's dividend payout ratio is 13.39%.

Insider Buying and Selling

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares of the company's stock, valued at $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.38% of the stock is owned by insiders.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.